Drugs.com - New Drug Approvals

FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

On January 22, 2025, Medexus was informed that the FDA approved Grafapex, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients one year of...

Feb 9, 2025 - 22:25
 0
FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
On January 22, 2025, Medexus was informed that the FDA approved Grafapex, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients one year of...
Read More

Tags:

Previous Article

FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of...

Next Article

Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for...

Related Posts

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xa...

Feb 24, 2025  0

FDA Approves Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) for Prevention of Invasive Meningococcal Disease Caused by Serogroups A, B, C, W, and Y

FDA Approves Penmenvy (meningococcal groups A, B, C, W,...

Feb 17, 2025  0

FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

FDA Approves Symbravo (meloxicam and rizatriptan) for t...

Feb 9, 2025  0